Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hamburg Trumpets Potential Rewards Of Quality Improvement For Generic Industry

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA Commissioner takes a softer tone in repeating the message that quality must improve in the generics industry, saying the reward may manifest in inspection policy.

You may also be interested in...



FDA “Broad Agency Announcement” To Fund Generic, Clinical Design Research

Agency expects to provide $200,000 to $50 million on a wide range of research proposals to support regulatory science and innovation.

FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections

CDER’s Woodcock says the new database will drive risk-based inspection decisions.

GDUFA Success Depends On Industry Changes As Much As Review Improvements, FDA Says

“This is a shared responsibility. We have to have a shared sense of urgency,” Acting OGD director tells GPhA.

Related Content

Topics

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel